| Dr Mustafa M Rawaf, DO | |
|
8950 W Tropicana Ave Ste 1, Las Vegas, NV 89147-8138 | |
| (702) 790-2701 | |
| Not Available |
| Full Name | Dr Mustafa M Rawaf |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 14 Years |
| Location | 8950 W Tropicana Ave Ste 1, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114241973 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | DO1733 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Rose Dominican Hospitals - Siena Campus | Henderson, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Focus Mental Health Solutions Bhushan Manjooran Wirjo Pllc | 9537312863 | 17 |
News Archive
A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease, according to new research led by Harvard T.H. Chan School of Public Health.
Former vice president Dick Cheney, at 71, who has survived five heart attacks and years of heart failure, is recuperating in intensive care at a Northern Virginia hospital after undergoing a heart transplant Saturday. He had been on the waiting list for 20 months.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
DSM Biomedical, a global leader in biomedical materials science, today announced the extension of its partnership with CID based on the use of DSM ComfortCoat® Hydrophilic coating technology on the Optima Jet Stent Delivery System and the Fluydo PTCA Balloon Catheter, both with CE marked and launched on the European market last month.
› Verified 7 days ago
| Entity Name | State Of Nevada |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760572010 PECOS PAC ID: 9234022153 Enrollment ID: O20040212000160 |
News Archive
A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease, according to new research led by Harvard T.H. Chan School of Public Health.
Former vice president Dick Cheney, at 71, who has survived five heart attacks and years of heart failure, is recuperating in intensive care at a Northern Virginia hospital after undergoing a heart transplant Saturday. He had been on the waiting list for 20 months.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
DSM Biomedical, a global leader in biomedical materials science, today announced the extension of its partnership with CID based on the use of DSM ComfortCoat® Hydrophilic coating technology on the Optima Jet Stent Delivery System and the Fluydo PTCA Balloon Catheter, both with CE marked and launched on the European market last month.
› Verified 7 days ago
| Entity Name | Focus Mental Health Solutions Bhushan Manjooran Wirjo Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336483742 PECOS PAC ID: 9537312863 Enrollment ID: O20130116000365 |
News Archive
A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease, according to new research led by Harvard T.H. Chan School of Public Health.
Former vice president Dick Cheney, at 71, who has survived five heart attacks and years of heart failure, is recuperating in intensive care at a Northern Virginia hospital after undergoing a heart transplant Saturday. He had been on the waiting list for 20 months.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
DSM Biomedical, a global leader in biomedical materials science, today announced the extension of its partnership with CID based on the use of DSM ComfortCoat® Hydrophilic coating technology on the Optima Jet Stent Delivery System and the Fluydo PTCA Balloon Catheter, both with CE marked and launched on the European market last month.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mustafa M Rawaf, DO 660 S Green Valley Pkwy., Suite 140, Henderson, NV 89052-1964 Ph: (702) 790-2701 | Dr Mustafa M Rawaf, DO 8950 W Tropicana Ave Ste 1, Las Vegas, NV 89147-8138 Ph: (702) 790-2701 |
News Archive
A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease, according to new research led by Harvard T.H. Chan School of Public Health.
Former vice president Dick Cheney, at 71, who has survived five heart attacks and years of heart failure, is recuperating in intensive care at a Northern Virginia hospital after undergoing a heart transplant Saturday. He had been on the waiting list for 20 months.
EpiCept Corporation announced today that it has entered into a definitive agreement with a single life science focused institutional investor for the purchase of 1,065 shares of its new Series B 0% Convertible Preferred Stock at $1,000 per share, which are convertible into an aggregate of approximately 6.3 million shares of its common stock, and five-year warrants to purchase up to approximately 3.1 million shares of its common stock at an exercise price of $0.17 per share that are immediately exercisable.
Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.
DSM Biomedical, a global leader in biomedical materials science, today announced the extension of its partnership with CID based on the use of DSM ComfortCoat® Hydrophilic coating technology on the Optima Jet Stent Delivery System and the Fluydo PTCA Balloon Catheter, both with CE marked and launched on the European market last month.
› Verified 7 days ago
Dr. Ejine Okoroafor, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5440 W Sahara Ave, Suite 202, Las Vegas, NV 89146 Phone: 914-426-7774 | |
Dr. Garet Jefferson Zaugg, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2020 Wellness Way Ste 300, Las Vegas, NV 89106 Phone: 702-432-2233 Fax: 702-800-5456 | |
Dr. Muhammed A Hyder, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2465 E Twain Ave, Las Vegas, NV 89121 Phone: 702-789-6201 Fax: 304-522-0686 | |
Dr. Krista Linn Pinard, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3016 W Charleston Blvd Ste 150, Las Vegas, NV 89102 Phone: 702-790-2701 | |
Gobinder S. Chopra, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6410 Medical Center St Ste A100, Las Vegas, NV 89148 Phone: 702-796-8500 Fax: 702-796-8502 | |
Eden Santiago Lee, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3014 W Charleston Blvd Ste 130, Las Vegas, NV 89102 Phone: 702-671-6475 Fax: 702-671-6440 | |
John Reitano, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 S Rancho Dr, Ste I62, Las Vegas, NV 89106 Phone: 702-897-7250 Fax: 702-706-4838 |